Latest news with #VEGF
Business Wire
a day ago
- Business
- Business Wire
MarkHerz Signs MOU with TUM Hospital for Joint Development of Cardiovascular and Diabetes-Targeted AAV Gene Therapies
MUNICH--(BUSINESS WIRE)-- MarkHerz Inc., a biotechnology company specializing in AAV-based gene therapies targeting cardiovascular and metabolic diseases, announced that it has signed a Memorandum of Understanding (MOU) on May 16, 2025 with Klinikum rechts der Isar, the university hospital affiliated with the Technical University of Munich (TUM), Germany. 'This partnership goes beyond R&D it marks the beginning of international clinical and commercial deployment of our platform technology.' The agreement aims to establish a broad-based collaboration on the joint research and development of next-generation gene therapies for ischemic heart and peripheral vascular diseases. This will center around MarkHerz's proprietary MAAV Platform, which enables the development of precision-targeted AAV gene therapies, particularly its MRTF-A candidate. The collaboration will include preclinical and clinical trials, technology consulting, and the sharing of research infrastructure. The signing ceremony was attended by leading cardiovascular gene therapy expert Prof. Christian Kupatt (MD, TUM), patent attorney Dr. Rudolph Schön of Germany's Neymeyr & Partner, Seungmin Lee (Dr. Mark Lee), CEO of MarkHerz, and Jeongseo Baek (Grace Baek), Head of the company's German office. Building a Strategic Gateway into the European Clinical Landscape MarkHerz's entry into Germany reflects a strategic initiative to complement Korea's increasingly regulated domestic environment by leveraging Europe's flexible clinical trial pathways, such as EMA's Early Access programs and Investigator-Initiated Trials. TUM Hospital's extensive cardiovascular preclinical models and translational research capacity are expected to generate high-quality data recognized by global regulatory agencies, including the EMA, FDA, PMDA, and MFDS. Dr. Seungmin Lee emphasized, 'The clinical validation of cardiovascular gene therapies is a critical factor in licensing negotiations with global pharma partners. This partnership goes beyond R&D it marks the beginning of international clinical and commercial deployment of our platform technology.' MRTF-A gene therapy: expanding the horizons of regenerative medicine MarkHerz's MRTF-A treatment aims to overcome the limitations of existing protein-based treatments, such as VEGF and FGF, by promoting functional blood vessel regeneration through endothelial recovery. This treatment is designed to deliver long-term efficacy in a single dose while addressing the core promise of gene therapy: sustained, one-time treatment. The company's vector innovations using AAV9, AAVrh74 and AAV-LK03, optimized for specific organ targeting, establish a platform for expansion beyond rare diseases into cardiovascular and neurological diseases, aligning with global trends and further validating the scalability of the technology. Deepening Ties with Europe's Leading Research Ecosystem This agreement positions MarkHerz to strengthen ties with not only TUM, but also Ludwig Maximilian University (LMU) Munich and the BioM Cluster, forming a robust network across Europe's premier scientific institutions. These partners represent the heart of Europe's innovation engine, together having produced more than 50 Nobel laureates and offer broad potential for collaboration across biotechnology, neuroscience, and translational medicine. Dr. Rudolph Schön noted, 'Successful gene therapy commercialization in Europe requires a seamless integration of regulation, technology, and strategic partnerships. This MOU represents a vital first step.' Prof. Kupatt added, 'This agreement is a turning point, translating years of research into clinical and commercial reality.' A Global Bridge Strategy Beyond Borders MarkHerz is pursuing a 'global bridge' strategy that aims not only to transfer technology or engage in joint research, but to actively overcome structural barriers in Korea's biotech ecosystem, such as regulatory bottlenecks, limited venture investment, and a high reliance on large conglomerates. 'Korea's biotech sector is rapidly growing but still faces fundamental challenges,' said Dr. Seungmin Lee. 'Through this Korea-Germany partnership, MarkHerz aims to lead by example and establish a new model for successful global clinical and commercial integration.' MarkHerz currently collaborates with over 250 partner institutions and, through formal alliances with 15 of them, operates eight distinct pipelines. Notably, active joint research projects valued at approximately KRW 15 billion are underway in AAV-based cardiovascular therapies (licensed in 10 European countries), diabetes treatments, cerebrovascular disorder therapies and CAR-Treg–based cancer immunotherapies.
Yahoo
2 days ago
- Business
- Yahoo
CirCode Biomed gains clearance from FDA for RNA drug HM2002
CirCode Biomed's circular RNA drug HM2002 has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) for the treatment of ischaemic heart disease. HM2002 has also been approved by China's National Medical Products Administration (NMPA) in January 2025. This global endorsement allows CirCode to conduct clinical studies in patients suffering from ischaemic heart disease. HM2002 offers several advantages due to its composition of circular RNAs, which provide improved stability and low immunogenicity. The drug is designed to safely and continuously express vascular endothelial growth factor (VEGF) within the myocardium. This mechanism promotes angiogenesis, enhances myocardial perfusion and aids in recovering cardiac function. CirCode CEO Dr Chenxiang Tang stated: 'To promote angiogenesis and relieve ischaemia through VEGF overexpression is a well-tested solution, but there is a tremendous challenge to achieve an efficient, persistent and controllable expression of VEGF in vivo. 'A single dose of HM2002 can express VEGF protein for a perfect time window in vivo: long enough for efficient angiogenesis, short enough for any safety concerns. Once the microcirculation is reformed, it brings long-lasting benefits to patients without the presence of HM2002 or VEGF protein.' Preclinical studies have shown that HM2002 demonstrates safety and efficacy profiles. In a first-in-human investigator-initiated trial commenced at Ruijin Hospital, China, in 2024, all subjects exhibited significant improvements in cardiac function without any reported adverse events. CirCode co-founder, chairman and chief technology officer Yun Yang stated: "CirCode's robust, proprietary circular RNA platform laid the foundation for the fast IND approval of HM2002. With the help of our AI tools, we were able to leap from a concept to IND approval of HM2002 in less than two years. 'We have now built a strong pipeline portfolio in various fields such as therapeutic proteins, vaccines and in vivo CAR-T, covering multiple therapeutic areas such as cardiovascular diseases, infectious diseases, autoimmune diseases and oncology.' "CirCode Biomed gains clearance from FDA for RNA drug HM2002" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
5 days ago
- Business
- Yahoo
CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world's first circular RNA drug being administrated in patients
SHANGHAI, May 30, 2025 /PRNewswire/ -- Shanghai CirCode Biomed Co. Ltd. (CirCode), an innovative biotech company pioneering circular RNA therapies, recently announced that its leading pipeline HM2002 received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for ischemic heart disease on May 30, 2025. With the first patient administrated on September of 2024 in an investigator initiated trial (IIT), HM2002 is the world's first circular RNA drug ever being used in patients. It received IND approval from the National Medical Products Administration (NMPA) of China on January 10th, 2025. HM2002 is currently the first circular RNA therapy to receive IND clearance in both China and the United States, and is also the only circular RNA drug globally approved for clinical study on patients with ischemic heart disease. With the global aging population, ischemic heart disease shows a steadily rising incidence, and has been the leading cause of death globally for the past decades. The current standard of care shows limited effects in promoting myocardial microcirculation reconstruction and angiogenesis, leading to suboptimal efficacy and limited benefit in 10-year survival. There is an urgent unmet medical need for next generation therapies to improve patients' prognosis and quality of life. With the advantages of improved stability and low immunogenicity from circular RNAs, HM2002 can safely and continuously express vascular endothelial growth factor (VGEF) in the myocardium, which promotes angiogenesis, improves myocardial perfusion, and facilitates cardiac function recovery. It has demonstrated excellent safety and efficacy in the preclinical studies. In the first-in-human IIT at Ruijin Hospital initiated last year, all subjects showed significant cardiac function improvement without any drug-related adverse events. "To promote angiogenesis and relief ischemia through VEGF overexpression is a well-tested solution, but there is a tremendous challenge to achieve an efficient, persistent, and controllable expression of VEGF in vivo. We find an excellent match between the need and the properties of circular RNA. A single dose of HM2002 can express VEGF protein for a perfect time window in vivo: long enough for efficient angiogenesis, short enough for any safety concerns. Once the microcirculation reformed, it brings long-lasting benefits to patients without the presence of HM2002 or VEGF protein," said Dr. Chenxiang Tang, CEO of CirCode. "The IND clearances from both NMPA and FDA for HM2002 is a strong recognition for our innovation and competitiveness in the circular RNA therapeutic industry. Dr. Yun Yang, co-founder, chairman, and chief technology officer of CirCode, stated that, "CirCode's robust, proprietary circular RNA platform laid the foundation for the fast IND approval of HM2002. With the help of our AI tools, we were able to leap from a concept to IND approval of HM2002 in less than 2 years. We now have built a strong pipeline portfolio in various fields such as therapeutic proteins, vaccines, and in vivo CAR-T, covering multiple therapeutic areas such as cardiovascular diseases, infectious diseases, autoimmune diseases, and oncology. These pipelines have showed a favorable risk benefit profile with great efficacy and safety data in preclinical settings, many of which will enter the clinical stage within the next year. We are so excited to keep pushing the frontier of circular RNA therapy forward and providing more innovative therapies for patients." About CirCode CirCode is a clinical-stage biotechnology company specializing in circular RNA therapeutics. Leveraging strong science and deep know-how, the company has built a fully integrated and proprietary platform, protected by a comprehensive global patent network, paving the way for the development of circular RNA therapeutics. Focusing on unmet medical needs, CirCode has built a robust pipeline targeting vaccines, cardiovascular diseases, autoimmune disorders, and oncology. CirCode is backed by top-tier investors and has received strong recognitions from leading pharmaceutical companies. Circode is committed to promoting the transformation of scientific and technological achievements and realizing the benefit of science and technology for mankind. More information please visit Or contact info@ for business cooperation. View original content to download multimedia: SOURCE Shanghai CirCode Biomed Co. Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
New Summit data could slow US approval plans for PD-1/VEGF drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A dual-acting drug developed by Summit Therapeutics and Akeso delayed tumor progression in a Phase 3 lung cancer trial but didn't extend survival, complicating its potential path to approval in the U.S. When administered alongside chemotherapy, the drug, known as ivonescimab, reduced the risk of death or disease progression by 48% compared to chemotherapy alone in patients whose non-small cell lung cancer has a mutation in a gene called EGFR. However, a 21% reduction in death risk, specifically, didn't meet the threshold for statistical significance, Summit said in a statement Friday. Summit intends to seek Food and Drug Administration approval based on the study results. Yet in its statement, the company indicated the timing of a filing is uncertain given the agency has made clear that a survival benefit is 'necessary' to support a submission. Summit shares fell by nearly 20% early Friday. Ivonescimab is the frontrunner among more than a dozen medicines that simultaneously block the proteins PD-1 and VEGF and are seen as a way to build upon widely used cancer immunotherapies like Keytruda. Its success or failure has broad implications for cancer research, making each study readout a closely scrutinized event among scientists and investors. So far, the results Summit and its China-based partner Akeso have accrued are painting a mixed and incomplete picture. A Phase 3 trial in China in non-small cell lung cancer found the drug cut the risk of disease progression or death in half compared to Keytruda, a striking, first-of-its-kind result that sparked interest and investment in PD-1/VEGF drugs. But ivonescimab hasn't yet clearly extended survival in that same study. Summit's drug also hasn't yet proven superior to the Keytruda-chemotherapy regimen that's standard therapy in many lung cancers. The results accrued so far were from trials in China, too, not the kind of multi-country test the FDA prefers. The data revealed Friday were meant to address one of those issues, proving that the benefits Summit and Akeso have observed in China would be replicated in a broader study population. Summit, for its part, said invonescimab's effects on tumor progression were 'clinically meaningful' in 'both Asia and ex-Asia sub-populations,' and demonstrated the 'consistency' of the drug's benefit in each group. The outcome also closely resembled what Akeso reported in a similar study of EGFR-mutated lung cancer in China. No new safety issues were observed either. The data 'demonstrates the potential benefit ivonescimab has to bring to patients around the world, including the United States,' said Summit chairman and co-CEO Robert Duggan, in a statement. Still, the lack of a clear impact on survival in the trial, at least so far, could slow ivonescimab's path to approval in the U.S. Summit implied its results could improve, as the follow-up time for 'western' patients in its trial was less than the median overall survival figure when data were analyzed. It also noted how no FDA-approved regimens in the setting in which ivonescimab was tested have demonstrated a statistically significant effect on survival. The FDA's insistence on such data, though, 'will weigh into Summit's considerations' as to when it might make a submission, the company said. The agency's 'high bar for demonstrated overall survival benefit make approval less likely,' wrote Leerink Partners analyst Daina Graybosch, in a Friday note to investors. Just this week, Merck and Daiichi Sankyo withdrew an approval application in EGFR lung cancer after a drug they've been developing failed to improve survival in a clinical trial. Summit will disclose specific findings at a future medical meeting. A study evaluating ivonescimab and chemotherapy against Keytruda and chemotherapy in non-small cell lung cancer is ongoing. A readout is expected in 2027, according to a federal database. Recommended Reading New Akeso, Summit data stir debate on PD-1/VEGF drugs
Yahoo
22-05-2025
- Health
- Yahoo
FDA approves Roche's Susvimo for diabetic retinopathy
Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine months Susvimo's innovative technology via the Port Delivery Platform may offer an alternative to regular eye injections in the US Diabetic retinopathy affects almost 10 million people in the US and is the third FDA-approved indication for Susvimo, which is also approved for treating neovascular or 'wet' age-related macular degeneration and diabetic macular edema Basel, 22 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR), a potentially blinding condition that affects almost 10 million people in the US and more than 100 million people globally.1,2 It is the first and only FDA-approved continuous delivery treatment shown to maintain vision in people with DR with just one refill every nine months.3,4 Susvimo is now available to US retina specialists and their patients with DR who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. 'The approval of Susvimo for diabetic retinopathy expands treatment options for patients, offering predictable and immediate durability after implantation with only one treatment every nine months,' said Levi Garraway, MD, PhD, Chief Medical Officer and Head of Global Product Development. 'Many patients with common retinal conditions seek alternative treatment options like Susvimo that can help preserve vision with longer intervals between treatments than regular eye injections.' 'Susvimo is a compelling new treatment for patients at risk of vision loss from progression of diabetic retinopathy,' said vitreoretinal surgeon, Carl Awh, M.D., Tennessee Retina, Tennessee. 'I am delighted to have this far more durable treatment available for my patients.' The FDA decision was based on positive one-year results from the phase III Pavilion study. People with DR who received Susvimo refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale (DRSS).4 This means there was a reduction in the severity of eye damage caused by diabetes, compared with those under monthly clinical observation who were treated with anti-VEGF injections as needed based on disease progression.4 Additionally, none of the participants receiving Susvimo required supplemental treatment at one year.4 Safety was consistent with the known safety profile for Susvimo.4 Susvimo provides continuous delivery of a customised formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require eye injections as often as once per month.5,6 The Port Delivery Platform is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure, which introduces medicine directly into the eye, addressing certain retinal conditions that can cause vision loss.5,6 Roche is focused on saving people's eyesight from the leading causes of vision loss through pioneering therapies and has the broadest retina pipeline in ophthalmology, which is led by science and informed by insights from people with eye conditions. About diabetic retinopathyAccounting for approximately 5% of all cases of visual impairment, diabetic retinopathy (DR) occurs when damage to the blood vessels and the formation of new blood vessels causes blood and/or fluid to leak into the retina - a part of the eye that sends information to the brain, enabling sight.7,8 This leads to swelling, as well as blockage of the blood supply to some areas of the retina.9 As the condition progresses, vision becomes impaired.8 DR affects approximately 103 million people globally, resulting in blindness in almost five million people.2,10 About the Pavilion study11Pavilion (NCT04503551) is a multicentre, randomised, US-based phase III study evaluating the efficacy, safety and pharmacokinetics of Susvimo® (Port Delivery Platform with ranibizumab) 100 mg/mL refilled every nine months compared with people under monthly clinical observation, in 174 people with non-proliferative diabetic retinopathy (DR) without centre-involved diabetic macular edema. Participants were randomised 5:3 to receive either Susvimo with refills every nine months or monthly clinical observation, respectively. In the Susvimo arm, participants received two loading doses of intravitreal ranibizumab, before Susvimo implantation at week 4. The primary endpoint was the proportion of participants with at least a two-step improvement from baseline on the Early Treatment Diabetic Retinopathy Study-Diabetic Retinopathy Severity Scale at week 52. Following the primary analysis, participants initially in the clinical observation arm received two ranibizumab loading doses before Susvimo implantation at week 64. About Susvimo® (Port Delivery Platform with ranibizumab) in the USSusvimo is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure. Susvimo continuously delivers a customised formulation of ranibizumab over time.6 Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor designed to bind to and inhibit VEGF-A, a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels.12 The customised formulation of ranibizumab delivered by Susvimo is different from the ranibizumab intravitreal injection, a medicine marketed as Lucentis® (ranibizumab injection)*, which is approved to treat neovascular or 'wet' age-related macular degeneration (nAMD) and other retinal diseases. Lucentis was first approved for nAMD by the US Food and Drug Administration in 2006.13 Roche is also developing DutaFabs – the next generation of bispecific antibodies designed for increased efficacy and durability – tailored for continuous delivery via the Port Delivery implant. About Roche in ophthalmologyRoche is focused on saving people's eyesight from the leading causes of vision loss through pioneering therapies. Through our innovation in the scientific discovery of new potential drug targets, personalised healthcare, molecular engineering, biomarkers and continuous drug delivery, we strive to design the right therapies for the right patients. We have the broadest retina pipeline in ophthalmology, which is led by science and informed by insights from people with eye conditions. Our pipeline includes innovative treatments across different modalities, such as antibodies, and gene and cell therapies targeting multiple vision-threatening conditions, including retinal vascular and diabetic eye diseases, geographic atrophy, and autoimmune conditions, such as thyroid eye disease and uveitic macular edema. Applying our extensive experience, we have brought breakthrough ophthalmic treatments to people living with vision loss. Susvimo® (previously called Port Delivery System with ranibizumab) 100 mg/mL for intravitreal use via ocular implant is the first US Food and Drug Administration-approved refillable eye implant for neovascular or 'wet' age-related macular degeneration (nAMD), diabetic macular edema (DME) and diabetic retinopathy (DR) that continuously delivers a customised formulation of ranibizumab over a period of months.3,6 Vabysmo® (faricimab) is the first bispecific antibody approved for the eye, which targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 and vascular endothelial growth factor-A.14-16 Vabysmo is approved around the world for people living with nAMD, DME and macular edema following retinal vein occlusion.16-21 Lucentis® (ranibizumab injection)* was the first treatment approved to improve vision in people with certain retinal conditions.13 About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit *Lucentis® (ranibizumab injection) was developed by Genentech, a member of the Roche Group. Genentech retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world. All trademarks used or mentioned in this release are protected by law. References[1] Lundeen EA, et al. Prevalence of diabetic retinopathy (DR) in the United States (US) in 2021. JAMA Ophthalmol. 2023 Aug 1;141(8):747-754.[2] Teo ZL, et al. Global prevalence of DR and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021 Nov;128(11):1580-1591.[3] US Food and Drug Administration (FDA). Highlights of prescribing information, Susvimo. 2021. [Internet; cited April 2025]. Available from: [4] Pieramici D. Port Delivery System (PDS) with ranibizumab in patients with DR: Primary analysis results of the phase III Pavilion trial. Presented at: The Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration Annual Meeting; 2023 Feb 10-11; virtual.[5] National Eye Institute. Injections to treat eye conditions. [Internet; cited April 2025]. Available from: [6] Holekamp N, et al. Archway randomised phase III trial of the PDS with ranibizumab for neovascular age-related macular degeneration (nAMD). Ophthalmology. 2021.[7] Shrestha P et al. Blindness among patients with type II diabetes mellitus presenting to the outpatient department of ophthalmology of a tertiary care centre: a descriptive cross-sectional study. J Nepal Med Assoc. 2022;1;60(254):877-880.[8] National Health Service (NHS). Overview. DR. How diabetes can affect the eyes. [Internet; cited April 2025]. Available from: [9] American Academy of Ophthalmology. Macular edema. [Internet; cited April 2025]. Available from: Harvard Medical School. Department of Ophthalmology. Diabetic eye disease. [Internet; cited April 2025]. Available from: Clinical A multicentre, randomised study in participants with DR without centre-involved diabetic macular edema (DME) to evaluate the efficacy, safety and pharmacokinetics of ranibizumab delivered via the PDS with ranibizumab relative to the comparator arm (Pavilion). [Internet; cited April 2025]. Available from: Heier JS, et al. The angiopoietin/tie pathway in retinal vascular diseases: A review. The Journal of Retinal and Vitreous Diseases. 2021;41:1-19.[13] US FDA. Highlights of prescribing information, Lucentis. 2012. [Internet; cited April 2025]. Available from: [14] Wykoff C, et al. Efficacy, durability and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with DME (YOSEMITE and RHINE): Two randomised, double-masked, phase III trials. The Lancet. 2022; 399:741-755.[15] Heier JS, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for nAMD (TENAYA and LUCERNE): Two randomised, double-masked, phase III, non-inferiority trials. The Lancet. 2022;399:729-40.[16] US FDA. Highlights of prescribing information, Vabysmo. 2024. [Internet; cited April 2025]. Available from: Roche data on file.[18] Medicines and Healthcare products Regulatory Agency approves faricimab through international work-sharing initiative. [Internet; cited April 2025]. Available from: Chugai obtains regulatory approval for Vabysmo, the first bispecific antibody in ophthalmology, for nAMD and DME. [Internet; cited April 2025]. Available from: European Medicines Agency. Summary of product characteristics, Vabysmo. [Internet; cited April 2025]. Available from: Chugai obtains regulatory approval for Vabysmo, the only bispecific antibody in the ophthalmology field, for additional indication of macular edema associated with retinal vein occlusion. [Internet; cited April 2025]. Available from: Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Nina MählitzPhone: +41 79 327 54 74 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Investor Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Attachment Media & Investor Release Susvimo DR FDA EnglishError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
